Literature DB >> 8134110

c-fos and c-jun overexpression in malignant cells reduces their tumorigenic and metastatic potential, and affects their MHC class I gene expression.

A Yamit-Hezi1, D Plaksin, L Eisenbach.   

Abstract

Reduced co-expression of the c-fos and c-jun protooncogenes has been correlated with the down regulation of H-2K class I major histocompatibility antigens in high-metastatic cell lines from the Lewis lung carcinoma, B16 melanoma and the K1735 melanoma. Transfection of c-jun and c-fos genes into the high metastatic clones D122 (3LL) and F10.9 (B16 melanoma) resulted in activation of H-2 class I gene expression. D122 transfectants expressing high levels of c-jun and c-fos and F10.9 transfectants expressing high levels of c-fos exhibited markedly reduced tumorigenicity and were of low metastatic potential. In contrast, transfection of junB into the low metastatic, high H-2Kb, Db expressor clone A9 (3LL), reduced MHC class I gene expression, and converted the parental low, into high-metastatic cells. The data demonstrate the involvement of genes from the fos and jun family in regulation of MHC class I expression and consequently in regulation of immunogenicity and metastatic competence of tumor cells.

Entities:  

Mesh:

Year:  1994        PMID: 8134110

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  4 in total

1.  Enhanced metastasis of B16 melanoma cells by unexpected elevated expression of the metastasis-associated TI-241 (LRF-1-, Jun-Fos-related) gene treated with antisense oligonucleotide.

Authors:  T Ishiguro; M Naito; K Hanaoka; H Nagawa; T Muto; T Tsuruo
Journal:  Clin Exp Metastasis       Date:  1998-02       Impact factor: 5.150

2.  A multiprotein complex consisting of the cellular coactivator p300, AP-1/ATF, as well as NF-kappaB is responsible for the activation of the mouse major histocompatibility class I (H-2K(b)) enhancer A.

Authors:  D Brockmann; B M Pützer; K S Lipinski; U Schmücker; H Esche
Journal:  Gene Expr       Date:  1999

3.  The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs.

Authors:  Ada Rephaeli; Michal Entin-Meer; Dikla Angel; Nataly Tarasenko; Tal Gruss-Fischer; Irena Bruachman; Don R Phillips; Suzanne M Cutts; Daphne Haas-Kogan; Abraham Nudelman
Journal:  Invest New Drugs       Date:  2006-09       Impact factor: 3.850

4.  Inhibitory effect of ATF3 antisense oligonucleotide on ectopic growth of HT29 human colon cancer cells.

Authors:  T Ishiguro; H Nagawa; M Naito; T Tsuruo
Journal:  Jpn J Cancer Res       Date:  2000-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.